ICAM1 and autoimmune thrombocytopenic purpura: In the current study, higher ICAM-1 could independently increase the negative risk in the achievement of response to low-dose decitabine, indicating that persistence of endothelial dysfunction might be attributable to refractory/resistance to existing ITP-specific treatments.